Through inhibiting SPOP-mediated degradation of LATS1, circXRN2 increases its stability. This activates the Hippo signaling pathway, which in turn decreases H3K18 lactylation and lowers LCN2 expression in bladder cancer. Here, LATS1 is linked to urinary bladder cancer.